麗珠醫藥(01513.HK)建議分拆麗珠試劑A股上市
格隆匯 8 月 9日丨麗珠醫藥(01513.HK)發佈公告,董事會於2020年8月7日舉行的會議上已審議並批准(其中包括)建議分拆珠海麗珠試劑股份有限公司A股上市的議案。
麗珠試劑於1989年在中國註冊成立。截至該公告日期,公司持有麗珠試劑約39.425%的股份,麗珠試劑為公司控股附屬公司。麗珠試劑主要從事診斷試劑及設備的研發、生產及銷售。
分拆麗珠試劑上市構成香港上市規則第15項應用指引界定的分拆上市,並須獲得香港聯交所批准。公司將就分拆麗珠試劑A股上市向香港聯交所作出申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.